ZUMA-1 trial: FDA approval and follow-up of CAR T-cell product axicabtagene ciloleucel

ZUMA-1 trial: FDA approval and follow-up of CAR T-cell product axicabtagene ciloleucel

VJHemOnc

2 years
173 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
Report 0 0
Category:
Description:
The Phase I/II trial ZUMA-1 (NCT02348216) was pivotal for CAR T-cell development. In this interview, Yi Lin, MD, PhD, of the Mayo Clinic, Rochester, MN, highlights how this led to FDA approval of the anti-CD19 second-generation CAR T-cell product, axicabtagene ciloleucel (axi-cel; KTE-C19), for refractory B-cell non-Hodgkin lymphoma (NHL). Dr Lin then discusses the exciting long-term follow-up data of this study. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Up Next Autoplay